StockData
Inmune Bio, Inc. logo

Inmune Bio, Inc. (INMB) stock

INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.96+0.01 (+1.44%)

Close on Nov 17, 2026Market cap $26.64MP/E –Yield –

Earnings

Inmune Bio's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q2 FY2025
–
EPS, Q2 FY2025
-$1.05
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Inmune Bio's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2025ended Sep 30, 2025Oct 30, 2025during market hours–––Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025during market hours––-$1.05Release
Q1 FY2025ended Mar 31, 2025May 8, 2025during market hours$50.00K–-$0.43Release
Q4 FY2024ended Dec 31, 2024Mar 27, 2025during market hours–––Release
Q3 FY2024ended Sep 30, 2024Nov 1, 2024during market hours––-$0.60Release
Q2 FY2024ended Jun 30, 2024Aug 2, 2024during market hours–––Release
Q1 FY2024ended Mar 31, 2024May 13, 2024during market hours–––Release
Q4 FY2023ended Dec 31, 2023Mar 29, 2024during market hours–––Release
Q3 FY2023ended Sep 30, 2023Nov 1, 2023during market hours$43.00K-56.1%-$0.48Release
Q2 FY2023ended Jun 30, 2023Aug 8, 2023during market hours$46.00K+187.5%-$0.36Release
Q1 FY2023ended Mar 31, 2023May 4, 2023during market hours$38.00K-81.0%-$0.36Release
Q4 FY2022ended Dec 31, 2022Mar 3, 2023during market hours–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Inmune Bio has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Inmune Bio puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Inmune Bio filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. Update
  3. Update
  4. Update
  5. News
  6. News
  7. News
  8. News
  9. News
  10. Update
  11. Update
  12. News
  13. News
  14. Update
  15. Update

See a number that looks wrong?